Member Info for MRK2020

I believe there was an area of decent grade Molybdenum on the BP site, that had been previously mined and that they could potentially reopen once revenue supports expansion

Thinking of investing. How do you see the RNS?

Branson... Laughed at that thanks

I disagree that this is a risky share at these levels. For new investors this is a great opportunity. With the major expansion underway, funded by the placement, and excellent products which they couldn't previously make enough quantity of, this should be making major strides.. I doubt there are many traders in this share at present but this week with interim results and the q and a should be significant. I too see this as a longterm superb prospect from these levels. I await details of sales and demand with interest, acknowledging the c19 factor.

Another pile of tiny trades today. A pattern repeated a few days this week.
Some days none at all, other days there are tens of them. I'm not convinced these are coincidental (as mentioned by others); but still none the wiser as to their meaning. Anyone confess to making those trades? or willing to interpret?

Hi Gin,
Given they are outsourcing some of the tasks, they may need less space. That said, you may also want a little bit of expansion room in a headquarters. I suspect the cost saving is as much to do with recession and a renter's market as size of premises or location. That said, it would be nice to have such details, rather than guessing. Their twitter page was last updated in March. The website is skant. Linkedin has some 'nice' clinical case studies though.
I will happily join a £1 party - it may come sooner than you think.
Looking forward to trading update; with fingers crossed.

Chester. I spotted the trade this morning (I don't have the specific time).
Noteworthy because I recall it was at 0.31.
MRK

some platforms do not charge per trade, for various reasons (e.g. over a certain volume of trades/subscription based)

https://www.hardmanandco.com/wp-content/uploads/2020/07/Hardman-Co-Monthly-August-2020.pdf
p37. it's a one pager broker summary of the business, with most of the info in Sandhopper's post below. All in all a positive read. And reiterates that the SP should pick up once the funded expansion and increased supply/sales takes off. It notes Covid-19 will have dimmed some of the initial increased sales potential due to deferred operations. IMO this is already reflected in the deflated SP. So, a very good time to buy if you can hold for a while, as price may be at low, and may rise prior to September interim results, but DYOR etc.
IVANS - no broker target price estimate therein.

That goes out to the gnomes too lol, at least IMO

To be fair concern over placing was fair. That said, a really good interview today providing a lot of reassurance. AP clarified a lot of the issues raised on this bb.. Re placing, assays, jorc, grades, production {underground and overground), financing... All positive. AP was clearly excited re the gold and silver results with current prices. He confirmed there would be further RNS next week (with further positive news). I have always considered production at BP the key success determinant.. And with that being delivered its looking up from here imp.

I've not seen this posted so apologies if I have missed but within the fundraising RNS is a link to the commercial prospectus that accompanied the sale. It provides a neat summary of the key areas of business (updating some areas from the annual report). It is available at: https://www.sec.gov/Archives/edgar/data/1723069/000121390020020182/ea124966-424b5_tizianalife.htm#T24

Eg Stemprinter summary therein.
StemPrintER is a multi-gene signature assay intended for use as a prognostic tool in patients with estrogen-receptor positive ER+/HER2 negative breast cancers. This in-vitro prognostic test can be used in conjunction with clinical evaluation to identify those patients at increased risk for early and/or late metastasis to help physicians distinguish ER+/HER2 negative patients. Two posters were selected for presentation at virtual ASCO 2020 Conference. One demonstrating the superiority of StemPrintER stem cell based genomic prognostic tool versus the market leader, Oncotype DX, in predicting recurrence in ER+/HER2- postmenopausal breast cancer patients was selected for discussion session. The second poster describing results on prediction of distant recurrence using a next generation StemPrintER model, named SPARE, presented in a separate ASCO session, showed even more refined accuracy than standard clinicopathological markers in predicting risk of distant recurrence. Both posters were authored by a team of scientists from the European Institute of Oncology in Milan, and the head-to-head comparison of StemPrintER with Oncotype DX was conducted in collaboration with the Royal Marsden Hospital and Queen Mary University in London.

On July 1, 2020, we announced plans to continue with “demerger” of the StemPRintER© technology and spin-off into a separate company. This event followed announcement on May 29, 2020 of results from a study showing that StemPRintER outperformed Oncotype DX in 10-year risk prediction in more than 800 ER+/HER2- postmenopausal breast cancer patients in the analysis, including in lymph node-negative (N0) and 1 to 3 lymph node-positive (N1-3) patients.

So.. We are to expect a II shareholder RNS in next day or so?

what's the timeframe re Atlas repayment, I don't have access to my notes as away.
i.e. when will the suppression of SP likely cease? / or in what circumstances if not timebound.

I'm thinking of topping up. I believe there will be a RNS Monday confirming progress. Hopefully it is worded well recognising the milestone of production appropriately. Any other details a welcome bonus. GLA

So the polygon and kite lake shorts were closed after the RNS yesterday. Great news for holders given all the games the shorter had been playing. Plus I'm hoping the board can have less of the antagonism and schadenfreude that accompanied them. That's me being polite of course.
Meanwhile onwards and upwards.

Should be a great week ahead with production confirmation to follow great RNS of Friday. Gla

Great RNS. I always had faith

Overall good news, and in line with expectations, so reassuring for the future cash and profit generation. I would have liked a lot more detail about the plans (perhaps will follow on their website or elsewhere?) but c'est la vie.

I agree that the RNS is boring. Contrast it with GGPs of yesterday. But in the wider scheme of things the start of production is massive. Credit where due for the acquisition and production delivery of this game-changing asset.